Gastroenterology

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Arcadia Consumer Healthcare Acquires Iconic Over-the-Counter Anti-Diarrheal Medicine Kaopectate®

Lead Product(s): Bismuth Subsalicylate

Therapeutic Area: Gastroenterology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Arcadia Consumer Healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 20, 2020

Details:

Acquisition further strengthens Arcadia's consumer healthcare product portfolio.

InDex Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation

Lead Product(s): Cobitolimod

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Vinnova

Deal Size: $0.1 million Upfront Cash: Undisclosed

Deal Type: Funding March 31, 2020

Details:

The grant will be used for a preclinical project to evaluate selected compounds from InDex's DIMS platform in inflammatory disease models outside the field of inflammatory bowel disease.

OrphoMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

Lead Product(s): ORP-101

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

OrphoMed has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D) in response to the COVID-19 pandemic.

Allakos

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Lead Product(s): Antolimab

Therapeutic Area: Gastroenterology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

Six-month treatment with antolimab resulted in a 64 percent mean reduction in TSS-8 compared to baseline.

Biostage

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant

Lead Product(s): Cellspan Esophageal Implant

Therapeutic Area: Gastroenterology

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2020

Details:

The FDA notified the Company that it removed the clinical hold and that the Company may proceed with its study.

Tetraphase Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

Lead Product(s): Eravacycline

Therapeutic Area: Gastroenterology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: AcelRx Pharmaceuticals

Deal Size: $26.9 million Upfront Cash: Undisclosed

Deal Type: Acquisition March 16, 2020

Details:

Tetraphase and AcelRx entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain.

Massachusetts General Hospital

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Royalty pharma acquires royalties on Entyvio from Massachusetts General Hospital

Lead Product(s): Vedolizumab

Therapeutic Area: Gastroenterology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Royalty Pharma

Deal Size: $94.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition March 05, 2020

Details:

Through transactions such as this, Royalty Pharma is furthering our goal of accelerating innovation and making the life sciences research and development ecosystem more efficient and productive.

Innovation Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis

Lead Product(s): Brilacidin

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

Details:

The Company is presently interviewing Contract Research Organizations for site selection with the understanding that the goal is to initiate the trial this summer.

Cinclus Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophageal Reflux Disease

Lead Product(s): Linaprazan

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Fourth Swedish National Pension Fund

Deal Size: $25.6 million Upfront Cash: Undisclosed

Deal Type: Financing March 04, 2020

Details:

The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.

Takeda Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Takeda: Subcutaneous Formulation Of Vedolizumab Receives Positive CHMP Opinion

Lead Product(s): Vedolizumab

Therapeutic Area: Gastroenterology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2020

Details:

If approved, vedolizumab will become the only maintenance therapy for ulcerative colitis or Crohn's disease with both intravenous and subcutaneous formulations across the European Union.

Find

Find Gastroenterology Clinical Drug Pipeline Developments & Deals

A collaboration with SCORR Marketing

Product Type

Development Status

Sanofi

Arcadia Consumer Healthcare Acquires Iconic Over-the-Counter Anti-Diarrheal Medicine Kaopectate®

InDex Pharmaceuticals

InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation

OrphoMed

OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

Allakos

Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Biostage

Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant

Tetraphase Pharmaceuticals

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

Massachusetts General Hospital

Royalty pharma acquires royalties on Entyvio from Massachusetts General Hospital

Innovation Pharmaceuticals

Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis

Cinclus Pharma

Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophageal Reflux Disease

Takeda Pharmaceutical

Takeda: Subcutaneous Formulation Of Vedolizumab Receives Positive CHMP Opinion